Latest Capital Structure News

Raptis Group Limited has completed a $225,000 private placement and launched a fully underwritten $1.75 million entitlement offer, aiming to expand its property management portfolio with a possible Broadbeach acquisition.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

Alvo Minerals has voluntarily suspended trading of its shares on the ASX as it finalizes an Entitlement Offer and prepares to announce progress on the Lavra Velha Project acquisition.

Matrix Composites & Engineering has received a preliminary, non-binding proposal from Advanced Innergy Solutions for a reverse merger, prompting careful review by its board amid uncertainty.

QBE Insurance Group has finalised the resale and buyback of its US$400 million perpetual capital notes, leading to their cancellation and delisting from the Singapore Exchange.

Impact Minerals Ltd has successfully closed its renounceable rights issue, raising $635,000 and issuing over 105 million new shares alongside nearly 53 million options. The capital raise marks a significant step in bolstering the company’s funding position.

Bayan Mining and Minerals Limited has completed a $300,000 placement to its directors, issuing new shares and attaching options, signaling strong board confidence in the company’s future.

Almonty Industries reports steady tungsten market conditions and completes key financing for its Sangdong Mine, while posting a $34.6 million net loss in Q1 2025. The company advances its US Domestication and plans to restart Los Santos Mine in 2026.

Almonty Industries reported a sharp increase in net loss for Q1 2025 despite stable revenues, driven by significant non-cash charges on warrant and derivative liabilities. The company secured additional financing to support ongoing operations and project development.

Legacy Minerals Holdings has raised A$7.75 million through a strongly supported equity placement to accelerate drilling and exploration at its key Drake and Thomson projects in New South Wales.

Recce Pharmaceuticals has successfully raised A$8.4 million through an entitlement offer and placement to fund pivotal Phase 3 clinical trials, advancing its synthetic anti-infective pipeline towards commercialisation in 2026.

Aspen Group has successfully raised $70.18 million through an institutional placement, aiming to reduce debt and pursue new growth opportunities. A Security Purchase Plan is also underway for eligible investors.